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Cisplatin plus 5‐fluorouracil is regarded as standard neoadjuvant chemotherapy
for esophageal squamous cell carcinoma (ESCC) in Japan, but the prognosis
remains poor. We have previously described how definitive chemoradiotherapy
with docetaxel, nedaplatin, and 5‐fluorouracil (DNF) led to a very high response
rate and promising survival times. We therefore undertook a phase II trial to
evaluate the feasibility and efficacy of neoadjuvant DNF. The study included
patients with clinical stage Ib‐III ESCC. Chemotherapy consisted of i.v. docetaxel
(30 mg/m2) and nedaplatin (50 mg/m2) on days 1 and 8, and a continuous infu-
sion of 5‐fluorouracil (400 mg/m2/day) on days 1‐5 and 8‐12, every 3 weeks.
After three courses of chemotherapy, esophagectomy was carried out. The pri-
mary end‐point was the completion rate of the protocol treatment. Twenty‐eight
patients were enrolled (cStage Ib/II/III, 2/3/23) and all received at least two cycles
of chemotherapy. Twenty‐five patients underwent surgery, all of whom achieved
an R0 resection, leading to a completion rate of 89.3%. The overall response rate
was 87.0%. A pathological complete response was confirmed in eight (32.0%)
cases. Grade 3/4 adverse events included leukopenia (32.1%), neutropenia
(39.3%), febrile neutropenia (10.7%), thrombocytopenia (10.7%), and diarrhea
(14.3%), but were manageable. Treatment‐related deaths and major surgical com-
plications did not occur. Estimated 2‐year progression‐free and overall survival
rates were 70.4% and 77.2%, respectively. Thus, DNF therapy was well tolerated
and deemed feasible, with a strong tumor response in a neoadjuvant setting for
ESCC. This trial is registered with the University Hospital Medical Information
Network (UMIN ID: 000014305).
Abbreviations: 5-FU, 5-fluorouracil; CDDP, cisplatin; CDGP, nedaplatin (cis-diamine-glycolate platinum); CF, cisplatin plus 5-fluorouracil; CI, confidence interval; CR, complete response; CRT,
chemoradiotherapy; CT, computed tomography; DCF, docetaxel, cisplatin, and 5-fluorouracil; DNF, docetaxel, nedaplatin, and 5-fluorouracil; DOC, docetaxel; ESCC, esophageal squamous cell
carcinoma; G-CSF, granulocyte colony-stimulating factor; JCEC, Japanese Classification of Esophageal Cancer; JCOG, Japan Clinical Oncology Group; NAC, neoadjuvant chemotherapy;
NACRT, neoadjuvant chemoradiotherapy; OS, overall survival; pCR, pathological complete response; PFS, progression-free survival; PS, performance status; RR, response rate.
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1 | INTRODUCTION
Esophageal cancer is a highly malignant disease with a poor progno-
sis. Worldwide, in 2012, 456 000 cases of esophageal cancer were
diagnosed, and 400 000 people died from this life‐threatening dis-
ease. With an overall mortality to incidence ratio as high as 0.88,
esophageal cancer is the sixth leading cause of death due to a malig-
nant tumor.1
Continual improvements have been made in the treatment of
advanced esophageal cancer with surgery but these seem to have
plateaued, with a 5‐year OS rate of 50%‐60%.2 This has led to
urgently implementing a multimodality treatment approach, combin-
ing chemotherapy, radiotherapy, and surgery. In Europe and North
America, NACRT is regarded as standard treatment in response to
several studies describing significant improvements in OS by NACRT
followed by surgery for esophageal cancer, compared with surgery
alone.2,3 However, in Japan, such evidence has largely been disre-
garded, and the use of perioperative chemotherapy has instead been
investigated for the treatment of esophageal cancer.4,5 This is partly
because of differences in the histological type of tumor found, with
squamous cell carcinoma more likely to be identified in East Asian
countries, whereas adenocarcinoma accounts for about half of eso-
phageal cancer cases in Europe and North America. A disparity in
operative procedures, such as the extent of lymphadenectomy, has
also led to largely longer PFS in Japan compared to that in other
developed nations. Additionally, it is thought that NACRT might
increase the likelihood of postoperative complications.6,7
From the results of the JCOG9907 study, in which NAC was
deemed superior in terms of OS in comparison to adjuvant
chemotherapy, esophagectomy following two courses of CDDP plus
5‐FU (CF) is regarded as a standard strategy for resectable stage Ib‐
III ESCC.5 The rationales for the use of NAC included increasing cur-
ability by tumor reduction, and eradicating minimal residual disease
that could cause recurrence, among others; failure to achieve a
tumor response might result in an inability to undertake curative sur-
gery, or early recurrence after an operation. Therefore, a regimen
with strong antitumor activity is needed for NAC. The response rate
(RR) for neoadjuvant CF in the JCOG9907 study was limited to
38%; 2.5% of patients were considered to be unresectable because
of disease progression. Also, in a subgroup analysis of the study,
NAC therapy failed to benefit cohorts with advanced disease, such
as stage III or T3, compared with those with stage II or T1/T2. These
results suggest that a more effective regimen than CF is desirable,
especially for patients with an advanced tumor.
To improve the current poor rate of survival for ESCC, triple‐com-
bination regimens have been evaluated in recent years. Docetaxel
(DOC), a taxane‐derived agent that exerts antitumor efficacy by the
stabilization of microtubules, has shown effectiveness against ESCC.8
Combination chemotherapy with DCF, in which DOC is added to CF,
is regarded as one of the standard regimens in gastric cancer, as well
as in head and neck cancers, as judged from the results of phase III
studies in which DCF was superior to CF in terms of RR and OS.9-11
Good results with RR of 34.5%‐83.3% have also been reported in sev-
eral phase II trials of DCF for metastatic ESCC;12-16 this regimen was
thought to be a good candidate for NAC, leading to clinical studies in a
neoadjuvant setting. Two studies undertaken in Japan, mainly for
ESCC, revealed the promising efficacy of NAC‐DCF with RR of 53.7%‐
64.3%, an R0 resection rate of 92.0%‐98.0%, and a 2‐year survival rate
of 78.0%‐88.0%. However, severe hematological toxicities were
noted, with grade 3/4 and febrile neutropenia in 53.7%‐64.3% and
2.4%‐14.5% of patients, respectively. In addition, more than 40% of
patients experienced a postoperative complication, suggesting the
need for safer regimens.17,18
We previously undertook a phase I/II study of definitive CRT using
DOC and CDGP, which has almost the same antitumor activity and less
gastrointestinal and renal toxicity compared to CDDP,19,20 plus 5‐FU
(DNF). We subsequently showed strong anticancer efficacy with a RR
of 100% including a CR rate of 88.2%, and with a 2‐year PFS of 60.0%
in patients with stage Ib‐III disease. In addition, grade 3/4 and febrile
neutropenia were limited to 42.8% and 7.1%, respectively; cases with
grade 3/4 nephrotoxicity were not observed with a treatment comple-
tion rate of 94.7%, indicating a good tolerability of DNF.21
Based on these results, we concluded DNF was suitable for
NAC, and therefore undertook a phase II trial to evaluate the feasi-
bility and efficacy of NAC with DNF in patients with clinical stage
Ib‐III resectable ESCC.
2 | MATERIALS AND METHODS
2.1 | Patient eligibility
Eligibility criteria were as follows: histologically confirmed ESCC;
clinical stage IB‐III disease according to the UICC TNM classification
(7th edition);22 no prior chemotherapy or CRT; Eastern Cooperative
Oncology Group performance status (ECOG PS) of 0‐1; aged 20‐
80 years; adequate bone marrow function (leukocyte count >3000/
μL, neutrophil count >1500/μL, hemoglobin >8.0 g/dL, and platelet
count >100 000/μL); adequate liver function (serum bilirubin
level <1.5 mg/dL, and serum aspartate aminotransferase and alanine
aminotransferase levels less than twice the upper limit of normal);
adequate renal function (creatinine clearance ≥50 mL/min); life
expectancy of at least 3 months; no other serious medical condi-
tions; medically fit for surgery; no pregnancy or breast‐feeding; and
written informed consent.
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2.2 | Treatment and dose modifications
Treatment consisted of three cycles of DOC (30 mg/m2) and CDGP
(50 mg/m2) on days 1 and 8, and a continuous i.v. infusion of 5‐FU,
400 mg/m2/day, on days 1‐5 and 8‐12, repeated every 3 weeks.
Docetaxel was diluted in 250 mL normal saline and infused i.v. over
a period of 2 hours. Nedaplatin diluted in 500 mL saline was then
infused over 2 hours. After preparation in saline (250 mg/500 mL
saline), 5‐FU was drip‐infused continuously over a period of
120 hours. Concomitant medications routinely given i.v. before DOC
included 3 mg granisetron plus 6.6 mg dexamethasone. The prophy-
lactic use of antibiotics was not allowed. Granulocyte colony‐stimu-
lating factor was given when febrile or grade 4 neutropenia were
observed until symptoms recovered to grade 2. If G‐CSF was given,
prophylactic G‐CSF was allowed in subsequent cycles. If tolerability
was found in the first course, which was undertaken in hospital, then
chemotherapy in an outpatient setting was allowed for in subse-
quent cycles.
Chemotherapy was interrupted in the event of grade 3/4 hema-
tological toxicity, or grade 3/4 non‐hematological toxicity (except for
fatigue, nausea, and alopecia), and was resumed when an adverse
event resolved to grade 1 or less with a 10% reduction in doses of
all drugs. After the repeated occurrence of grade 3/4 toxicity in a
subsequent cycle, a 20% reduction of all drugs from baseline doses
was required. Any patient who required more than 4 weeks for
recovery from adverse reactions was taken off the study. Treatment
was also terminated when disease progression was observed, or
patients refused to continue.
Esophagectomy with three‐field lymphadenectomy (cervical, tho-
racic, and abdominal) was carried out 4‐8 weeks after the completion
of the last cycle of DNF. Surgery consisted of right thoracotomy fol-
lowed by laparotomy and a neck incision with cervical anastomosis.
Thoracoscopic surgery was allowed. Reconstruction was undertaken
using a gastric tube or the jejunum through a posterior mediastinal
route.
2.3 | Assessment and follow‐up
Pretreatment assessment included a physical examination, labora-
tory tests, a chest X‐ray, an esophagogastroduodenoscopy, and a
CT scan. Magnetic resonance imaging (MRI), 18F‐fluorodeoxyglu-
cose positron emission tomography/CT and/or radionuclide bone
imaging were also undertaken, if necessary. Bronchoscopy was car-
ried out if bronchial invasion by the tumor was suspected. During
treatment, a complete blood count, serum chemistry, and urinalysis
were undertaken at least twice a week. Toxicity was assessed
according to US NCI's Common Terminology Criteria for Adverse
Events (version 4.0).23
An assessment of responses to chemotherapy for measurable
lesions was undertaken with CT and/or MRI after each course of
chemotherapy according to RECIST guidelines version 1.1.24 The
response of the primary lesion was examined by endoscopy accord-
ing to the guidelines of the JCEC, 10th edition.25 An independent
review committee confirmed observed responses by radiological and
endoscopic examinations. Each patient was assessed every 3 months
after surgery for 1 year, then every 6 months for 4 years, and then
annually until death.
After surgery, the pathological response of the primary lesion
was also evaluated by JCEC according to the proportion of viable
tumor cells after chemotherapy as follows: grade 0, no part of tumor
affected; grade 1a, less than one‐third affected; grade 1b, between
one‐third and two‐thirds affected; grade 2, between two‐thirds and
entire tumor affected; and grade 3, no viable cancer cells (pCR).
Evaluations of residual tumor (R) were classified by the definition
listed in the 7th UICC TNM staging system.22 Surgical complications
were evaluated from the day of surgery until the time of discharge
according to the Clavien‐Dindo classification and its Japanese
extended version.26,27
2.4 | Study design and statistical analysis
The primary end‐point was to estimate the completion rate of the
protocol treatment. Patients were deemed to have completed the
protocol treatment when they received at least two courses of NAC
and achieved a pathologically complete resection (R0). Secondary
objectives included adverse events, RR including pathological
response, PFS, OS, R0 resection rate, and operative morbidity. Given
that the expected completion rate was 90% and the threshold inci-
dence was 70%, based on previously reported data in this cohort,5,17
with an alpha value of 0.1 (one‐sided) and a beta value of 0.1, the
required minimum number of patients was 25. The projected sample
size was 28 patients in total.
Progression‐free survival was defined as the time from the date
of registration to that of disease progression or death resulting from
any cause, and OS was measured from the date of registration to
that of death resulting from any cause. Statistical analyses were
undertaken using GraphPad Prism version 7.0d for Mac (GraphPad
Software, La Jolla, CA, USA; www.graphpad.com). Both PFS and OS
were analyzed according to the Kaplan‐Meier method and were
updated to February 1, 2018.
This study was registered at the University Hospital Medical
Information Network (UMIN ID: 000014305) and carried out in
accordance with the principles of the Declaration of Helsinki and
Ethical Guidelines for Medical and Health Research Involving Human
Subjects.28 The protocol was approved by the ethics committee of
each participating institution.
3 | RESULTS
3.1 | Patient characteristics
Patients’ characteristics are summarized in Table 1. Twenty‐eight
patients were enrolled from June 2014 to October 2017. The med-
ian age was 68.5 years (range, 52‐77 years), and most patients were
men (85.7%). All patients had an ECOG PS of 0 or 1. Approximately
70% of the patients had a T3/T4a tumor, and more than 80% were
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clinical stage III. All were assessed for both the presence of any
adverse events and their response to treatment.
3.2 | Treatment and compliance
The trial profile is shown in Figure 1. All patients received at least
two courses of NAC. Three patients discontinued the third cycle of
DNF and proceeded to surgery: two due to patient refusal and one
owing to disease progression. A dose reduction in NAC occurred in
seven patients in the second cycle and five in the third, mainly
because of neutropenia. Seven patients experienced a delay in treat-
ment of 7 days or more, due to protracted neutropenia in five cases
and thrombocytopenia in two. Of all 81 treatment cycles in the
study, 23 courses were undertaken by patients in an outpatient set-
ting.
In all, 25 patients received subsequent definitive surgery after
NAC. Two patients failed to undergo surgery because they were
deemed ineligible due to a low forced expiratory volume because of
pulmonary emphysema. One refused surgery. These three cases
received definitive CRT.
3.3 | Toxicity
Adverse events during chemotherapy are listed in Table 2. Leukocy-
topenia and neutropenia were major toxicities in 32.1% and 39.3%
of grade 3/4 cases, respectively. Grade 3 febrile neutropenia was
observed in 10.7% of patients. Although 10.7% of patients experi-
enced grade 3 thrombocytopenia, grade 4 cases were not observed.
In terms of non‐hematological toxicities, grade 4 events were not
observed, and grade 3 anorexia, diarrhea, stomatitis, and fatigue
were detected at rates of 32.1%, 14.3%, 7.1%, and 3.6%, respec-
tively. Grade 3/4 renal impairment was not observed in any patient.
All events resolved with appropriate care, and treatment‐related
deaths were not observed.
3.4 | Response
Table 3 shows the best overall response recorded during NAC
according to RECIST version 1.1. Of the 23 patients with measurable
lesions, 20 patients achieved a response (87.0%; 95% CI, 73.3%‐
100%), with four (17.4%) showing a CR. Of the five patients without
measurable lesions, a CR was observed in two cases (40.0%). A
patient who had confirmed stable disease after the first cycle of
chemotherapy showed progressive disease after the second course.
3.5 | Surgery and complications
Twenty‐five patients received surgery after NAC as listed in Fig-
ure 1. Surgical outcomes are shown in Table 4. Twenty patients
underwent a thoracoscopic subtotal esophagectomy with three‐field
lymphadenectomy, and a right thoracotomy was carried out in five
patients. Of the patients who underwent an esophagectomy, a radi-
cal R0 resection was achieved in all 25 cases, leading to a comple-
tion rate for protocol treatment of 89.3% (25/28; 95% CI, 77.9%‐
100%). Although postoperative complications were observed in
seven patients (28.0%), most of these were minor (Clavien‐Dindo
grade 1‐2). All major (Clavien‐Dindo grade 3‐5) complications were
grade IIIa; anastomotic stenosis in four cases, and one case each
showed a wound infection or chylothorax. These events resolved
with endoscopic dilation, antibiotics, and thoracic drainage, respec-
tively. Postoperative mortality was not observed.
A histopathologically complete response (grade 3) was achieved
in 8/25 patients, leading to a pCR rate of 32.0%. Grades 2, 1, and 0
TABLE 1 Characteristics of Japanese patients with resectable
esophageal squamous cell carcinoma treated with docetaxel,
nedaplatin, and 5‐fluorouracil
Characteristics No. of patients (n = 28) %
Age, years































†According to the UICC TNM system (7th edition).
Lt, lower thoracic esophagus; Mt, middle thoracic esophagus; Ut, upper
thoracic esophagus.
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were observed in 32.0%, 28.0%, and 8.0% of cases, respectively.
Pathological tumor and nodal status generally improved compared
with these prior to NAC, with eight cases showing no histological
evidence of a primary tumor (ypT0). Downstaging according to a
comparison between preoperative clinical and post‐surgery patholog-
ical stages was confirmed in 21 (84.0%) patients.
3.6 | Survival analysis
With a median follow‐up time of 27.2 months, the median PFS was
28.5 months, and 1‐/2‐year PFS rates were 76.8%/70.4% (Figure 2A);
the median survival time was not reached, and 1‐/2‐year OS rates
were 91.6%/77.2% (Figure 2B).
F IGURE 1 Profile of phase II study of
docetaxel, nedaplatin, and fluorouracil for
resectable esophageal cancer
TABLE 2 Toxicity of treatment with docetaxel, nedaplatin, and 5‐
fluorouracil in Japanese patients with resectable esophageal
squamous cell carcinoma
Toxicity grade (NCI‐CTC version
4.0)
Patients (n = 28)





White blood cell decreased 2 7 9 0 64.3 32.1
Neutrophil count decreased 2 6 5 6 67.9 39.3
Febrile neutropenia – – 3 0 10.7 10.7
Anemia 5 3 5 0 46.4 17.9
Platelet count decreased 5 1 3 0 28.6 10.7
Anorexia 4 7 9 0 71.4 32.1
Fatigue 7 6 1 0 50.0 3.6
Fever 1 0 0 0 3.6 0.0
Nausea 3 10 2 0 53.6 7.1
Vomiting 2 1 0 0 10.7 0.0
Mucositis oral 5 8 2 0 53.6 7.1
Constipation 4 1 0 0 17.9 0.0
Diarrhea 5 6 4 0 53.6 14.3
Alopecia 3 3 0 0 21.4 0.0
Edema 2 0 0 0 7.1 0.0
Sensory neuropathy 1 0 0 0 3.6 0.0
AST increased 6 0 0 0 21.4 0.0
ALT increased 9 0 0 0 32.1 0.0
ALP increased 0 1 0 0 3.6 0.0
Hyponatremia 3 0 1 0 14.3 3.6
Creatinine increased 2 1 0 0 10.7 0.0
Skin hyperpigmentation 2 0 0 0 7.1 0.0
–, a grade is not available. ALP, alkaline phosphatase; ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase; CTC, Common Toxicity Criteria.
TABLE 3 Response to treatment with docetaxel, nedaplatin, and
5‐fluorouracil in Japanese patients with resectable esophageal
squamous cell carcinoma
n %





Overall response rate 87.0†




†95% confidence interval, 73.3%‐100%.
CR, complete response; PD, progressive disease; PR, partial response;
SD, stable disease.
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During follow‐up, seven patients presented with locoregional
lymph node metastasis, two with distant organ metastasis, and one
with both locoregional and distant metastases. Of eight cases who
developed lymph node metastases, six involved cervical and superior
mediastinal lymph nodes. All seven patients with only locoregional
recurrence received definitive CRT, four of whom achieved a CR.
Three cases with distant metastases underwent chemotherapy.
4 | DISCUSSION
The current standard NAC used in Japan for ESCC is CF. However,
the prognosis of patients with this cancer continues to remain poor.
We previously found a high response rate and extended survival
times in such patients in response to definitive CRT with DNF. We
therefore undertook a phase II trial to evaluate the feasibility and
efficacy of neoadjuvant DNF in patients with resectable stage Ib‐III
ESCC. The treatment completion rate in the current study was
89.3%, with a 95% CI of 77.9%‐100%; this study met its primary
end‐point. To our knowledge, this is the first study to prospectively
examine DNF in a neoadjuvant setting.
Docetaxel, a microtubule inhibitor, CDGP, a DNA intrastrand
cross‐linking agent, and 5‐FU, an antimetabolite, have different
modes of action. This has led to the expectation of synergic effects
and a lack of cross‐resistance when these three drugs are used in
combination. Additionally, as these three agents show different
major adverse effects that can lead to dose‐limiting toxicities (DOC,
neutropenia; CDGP, thrombocytopenia; 5‐FU, diarrhea and mucosi-
tis), DNF is considered to be an ideal combination in terms of safety
and feasibility.
With regard to the dosing method used for DOC, several reports
have reported a lower incidence of adverse effects with a weekly
dose of DOC compared to a conventional schedule of every
3 weeks.29-31 Zimatore et al31 also observed a higher dose intensity
with a weekly schedule of DOC compared with a 3‐week administra-
tion in a comparative review. In addition, in our previous trial of
definitive CRT using DNF, in which a similar schedule was used, few
serious toxicities were observed.21 In contrast, in a phase II study
undertaken in Japan examining the 3‐week administration of DOC,
severe hematological toxicities were observed at an extremely high
rate of 88% for grade 3/4 neutropenia and 18% for febrile neutrope-
nia.8 Because of these observations, we adopted a weekly dosing
schedule for DOC in the present study.
Although CDDP is widely used for ESCC, it frequently induces
severe gastrointestinal toxicity and nephrotoxicity. Such adverse
effects as well as the requirement for a high volume of hydration,
recommended for the prevention of renal toxicity, limit the clinical
use of CDDP, especially in elderly patients who are at greater risk of
developing ESCC. Nedaplatin, a second‐generation platinum deriva-
tive, dissolves in water approximately 10 times more easily than
CDDP, leading to less nephrotoxicity, and a lack of need for
TABLE 4 Details of surgery in Japanese patients with resectable




Thoracoscopic surgery 20 80.0























ypStage 0 6 24.0
ypStage IA 5 20.0
ypStage IB 0 0.0
ypStage IIA 4 16.0
ypStage IIB 6 24.0
ypStage IIIA 0 0.0
ypStage IIIB 2 8.0
ypStage IIIC 2 8.0
Surgical complication
Recurrent laryngeal nerve palsy 4 16.0
Anastomotic leakage 1 4.0
Chylothorax 1 4.0
Gastrointestinal anastomotic stenosis 4 16.0
Wound infection 2 8.0
Pneumonia 1 4.0
Subcutaneous emphysema 1 4.0
†According to the UICC TNM system (7th edition).
‡According to the Japanese Classification of Esophageal Cancer (10th
edition).
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increased hydration.32 Zhang et al33 undertook a systematic review
comparing CDDP‐ and CDGP‐based chemotherapies for metastatic
or recurrent ESCC. They revealed that CDGP was comparable to
CDDP in terms of RR and OS, but showed less toxicity in terms of a
lower risk of nausea, vomiting, peripheral neuropathy, and nephro-
toxicity. The weekly dosing schedule of 50 mg/m2 CDGP was deter-
mined from our previous phase I study of CRT using 5‐FU and
CDGP.34 In the same phase I study, this 5‐FU was administered in
the same way as the current DNF regimen, and its tolerability was
shown.34 In addition, the dose intensity of 5‐FU in our trial is equal
to that in the JCOG9907 study (800 mg/m2/3 weeks), and therefore
its safety and efficacy are considered to be verified.5 Also, we postu-
late that 5‐FU, which induces time‐dependent cell growth inhibition,
should be administered for a long‐time so as to maximize its efficacy.
The schedule we chose for our DNF regimen was based on these
observations.
Regarding the dosing frequency of NAC, the JCOG9907 study
stipulated two courses of preoperative CF.5 In comparison, a trial
assessing DCF in a neoadjuvant setting reported a high completion
rate of 83% for three cycles of DCF.17 In addition to the above, all
patients in our trial of CRT using DNF completed two courses of
additional planned chemotherapy after CRT.21 Meredith et al35
reported that response and R0 resection rates after NAC correlated
with disease‐free survival and OS. Based on these results, we speci-
fied two to three courses of DNF as the protocol therapy for NAC,
after balancing the attributes of strong antitumor activity and feasi-
bility.
Concerning the safety of NAC, the tolerability shown in the
study was generally acceptable. The incidence of grade 3/4 neu-
tropenia was found to be 39.3%, which is lower than that observed
in studies using a DCF regimen (78.2%‐83.3%).17,18 Cases with grade
4 thrombocytopenia, a dose‐limiting toxicity of CDGP, were not
noted. Febrile neutropenia was observed in only 10.7% of patients
without grade 4 events. In the current study, prophylactic antibiotics
were not allowed, whereas the use of antibiotics for preventive pur-
poses is generally permitted outside of a clinical trial.36 Therefore,
on this basis, we can infer that the incidence of febrile neutropenia
will be lower in actual clinical practice. Cases with grade 4 non‐
hematological toxicity were not noted; patients also did not experi-
ence grade 3/4 nephrotoxicity, which is thought to be due to the
use of CDGP instead of CDDP. As such adverse events were tran-
sient and manageable, it is thought that this favorable safety profile
might have contributed to the high completion rate of NAC (two
courses, 100%; three courses, 89.3%).
The completion rate for the protocol treatment was high at
89.3%. This was thought to be partly because a high response rate
of 87.0% was achieved by DNF, which was higher than not only that
reported in JCOG9907 (38%) but also that in trials using DCF
(53.7%‐64.3%).5,7,18 In addition to using three potent agents, the
high completion rate was supported by the low proportion of
patients who needed a dose reduction or cessation of treatment; it
might also be associated with a high dose intensity, and therefore,
efficacy.
Despite a relatively short follow‐up period of 27.2 months, the
2‐year OS was 77.2%, which is comparable to that observed in trials
of DCF.17,18 In estimating long‐term survival, the high R0 resection
rate of 100% for patients who underwent surgery in the current
study is particularly meaningful. For example, Gertler et al37 analyzed
the prognoses of 2920 resected cases with esophageal cancer and
revealed that an R0 resection was an independent prognostic factor.
Others reached the same conclusion in a reproducible manner, so
the significance of an R0 resection as a prognostic factor is thought
to be well established.38,39 As with an R0 resection, it is noteworthy
that the pCR rate was 32.0%, which is markedly superior to that
obtained by CF (5%) and DCF (12%‐17%).5,17,18 The importance of a
pCR as a prognostic factor has been pointed out in previous
reports.40,41 Furthermore, Tomasello et al42 reported a meta‐analysis
of 17 studies with 3145 cases who received neoadjuvant therapy,
F IGURE 2 Kaplan‐Meier curves of progression‐free survival (A) and overall survival (B) in Japanese patients with resectable esophageal
squamous cell carcinoma treated with docetaxel, nedaplatin, and 5‐fluorouracil. The estimated 1‐year progression‐free and overall survival rates
were 76.8% and 91.6%, respectively
3560 | OHNUMA ET AL.
and found that a pathologic response was strongly associated with a
significant improvement in OS.
The rate of postoperative complications was found to be low,
with an incidence of 28%, with most events not considered severe.
In addition, mortality related to surgery was not noted. In particu-
lar, pneumonia, a major complication in surgery for esophageal can-
cer, was infrequent and mild, with only one case of grade 1
observed. One possible explanation for this favorable complication
profile is the high rate (80.0%) of patients who underwent thoraco-
scopic esophagectomy. It is thought that a large incision of the
chest by open thoracotomy prevents patients from taking deep
breaths after surgery and thus raises the risk of pneumonitis
because of atelectasis.43 In contrast, thoracoscopic esophagectomy
has been evaluated as a less invasive method; two prospective tri-
als have shown the safety of thoracoscopic esophagectomy com-
pared to conventional open surgery in terms of a reduced risk of
pneumonia.44,45 Although few studies have reported the incidence
of surgical morbidity, in two trials using DCF for NAC this was
shown to be 32%‐39% and included pneumonia. In these studies,
the proportion of patients who received thoracoscopic surgery was
less than 5%.16,46
Progression‐free survival in our study was almost identical to
that observed in a trial using DCF.17 However, of the 10 patients
who presented with recurrence in the current study, eight cases
developed locoregional lymph node metastasis. The prevention and
control of locoregional relapse is a crucial issue to be resolved
before further improvement in long‐term outcomes can be achieved.
Specifically, of the eight cases showing locoregional relapse, cervical
or superior mediastinal lymph node metastases were observed in six
patients. This might have been due to the difficulty of undertaking
cervical and superior mediastinal lymphadenectomies because of
anatomical constraints compared with those of lower mediastinal or
abdominal lesions. Countries in Asia have not been very proactive in
adopting non‐Asian evidence of NACRT thus far, as stated above.
However, in Japan, following promising results of good tolerability
and strong antitumor activity from a phase II study that investigated
NACRT with CF,47 a three‐arm phase III trial (JCOG1109) is now
ongoing to confirm DCF or CRT with CF as superior to CF as neoad-
juvant therapy for ESCC.48 In the near future, NACRT could become
one of the standard treatment options for resectable ESCC, depend-
ing on the result of JCOG1109, and, therefore, NACRT with DNF
might also need to be evaluated, as well as DNF, for NAC. Our pre-
vious trial of definitive CRT with DNF achieved an excellent tumor
response with a CR rate of 88.2% in stage Ib‐III cases;21 therefore,
further improvements in local control could be achieved by NACRT
with DNF. Nonetheless, this CRT regimen cannot be used in a
neoadjuvant setting in its original form, partly because of the differ-
ence in radiation dose: approximately 40 Gy of radiation is generally
accepted as a preoperative dosage, whereas definitive CRT with
DNF consists of 59.4 Gy. The establishment of an optimal treatment
schedule and a comparison with DNF for NAC in terms of efficacy
and safety are possible problems that should be resolved in the
future.
In conclusion, we have shown that combination chemotherapy
with DNF is a promising preoperative regimen for resectable ESCC,
showing an acceptable feasibility with a completion rate for proto-
col treatment of 89.3%, and strong antitumor efficacy. These
results were quite promising, but the existence of several limita-
tions of our investigation must be acknowledged, including the sin-
gle‐armed nature of the study, and the relatively small number of
patients recruited. Additional trials with larger cohorts and longer
follow‐up periods are needed to confirm the findings of the current
study.
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